Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 853-867

  Bussey, Kimberly J ^a   Chin, Koei ^b,d   Lababidi, Samir ^a,f   Reimers, Mark ^a   Reinhold, William C ^a   Kuo, Wen Lin ^b,d   Gwadry, Fuad ^a   Ajay, ^a,g   Kouros Mehr, Hosein ^b   Fridlyand, Jane ^b   Jain, Ajay ^c   Collins, Colin ^b,c   Nishizuka, Satoshi ^a   Tonon, Giovanni ^a   Roschke, Anna ^a   Gehlhaus, Kristen ^a   Kirsch, Ilan ^a   Scudiero, Dominic A ^e   Gray, Joe W ^b,d   Weinstein, John N ^a,e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e NATIONAL CANCER INSTITUTE   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g CELERA GENOMICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; ASPARTATE AMMONIA LIGASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BACTERIAL ARTIFICIAL CHROMOSOME; CANCER CELL; CARCINOGENESIS; CELL LINE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA MICROARRAY; DRUG ACTIVITY; DRUG RESPONSE; DRUG SENSITIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DNA, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KARYOTYPING; NEOPLASM PROTEINS; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; RNA, MESSENGER; RNA, NEOPLASM;

EID: 33646541046     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0155     Document Type: Article

References (54)

1. Bieche I, Lidereau R. Loss of heterozygosity at 13q14 correlates with RB1 gene underexpression in human breast cancer. Mol Carcinog 2000;29:151-8.
2. Bieche I, Laurendeau I, Tozlu S, et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. Cancer Res 1999;59:2759-65.
3. Smith CA, Pollice AA, Gu LP, et al. Correlations among p53, HER-2/ neu, and ras overexpression and aneuploidy by multiparameter flow cytometry in human breast cancer: evidence for a common phenotypic evolutionary pattern in infiltrating ductal carcinomas. Clin Cancer Res 2000;6:112-26.
4. Kristiansen G, Yu Y, Petersen S, et al. Overexpression of c-erbB2 protein correlates with disease-stage and chromosomal gain at the c-erbB2 locus in non-small cell lung cancer. Eur J Cancer 2001;37:1089-95.
5. Benz CC, Scott GK, Santos GF, Smith HS. Expression of c-myc, c-Ha-rasl, and c-erbB-2 proto-oncogenes in normal and malignant human breast epithelial cells. J Natl Cancer Inst 1989;81:1704-9.
6. Weinstein JN, Myers TG, O'Connor PM, et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997;275:343-9.
7. Shoemaker RH, Monks A, Alley MC, et al. Development of human tumor cell line panels for use in disease-oriented drug screening. Prog Clin Biol Res 1988;276:265-86.
8. Boyd MR, Paull KD. Some practical considerations and applications of the National Cancer Institute in vitro anticancer drug discovery screen. Drug Dev Res 1995;34:91-109.
9. Scherf U, Ross DT, Waltham M, et al. A gene expression database for the molecular pharmacology of cancer. Nat Genet 2000;24:236-44.
10. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:227-35.
11. Staunton JE, Slonim DK, Coller HA, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci U S A 2001;98:10787-92.
12. Myers TG, Anderson NL, Waltham M, et al. A protein expression database for the molecular pharmacology of cancer. Electrophoresis 1997;18:647-53.
13. Li G, Waltham M, Anderson NL, et al. Rapid mass spectrometric identification of proteins from two-dimensional polyacrylamide gels after in gel proteolytic digestion. Electrophoresis 1997;18:391-402.
14. Nishizuka S, Chen ST, Gwadry FG, et al. Diagnostic markers that distinguish colon and ovarian adenocarcinomas: identification by genomic, proteomic, and tissue array profiling. Cancer Res 2003;63:5243-50.
15. Nishizuka S, Charboneau L, Young L, et al. Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 2003;100:14229-34.
16. Roschke AV, Tonon G, Gehlhaus KS, et al. Karyotypic complexity of the NCI-60 drug-screening panel. Cancer Res 2003;63:8634-47.
17. Zhou Y, Gwadry FG, Reinhold WC, et al. Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: microarray analysis of dose- and time-dependent effects. Cancer Res 2002;62:1688-95.
18. Lee JK, Bussey KJ, Gwadry FG, et al. Comparing cDNA and oligonucleotide array data: concordance of gene expression across platforms for the NCI-60 cancer cells. Genome Biol 2003;4:R82.
19. Pinkel D, Segraves R, Sudar D, et al. High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 1998;20:207-11.
20. Massion PP, Kuo WL, Stokoe D, et al. Genomic copy number analysis of non-small cell lung cancer using array comparative genomic hybridization: implications of the phosphatidylinositol 3-kinase pathway. Cancer Res 2002;62:3636-40.
21. Snijders AM, Nowak N, Segraves R, et al. Assembly of microarrays for genome-wide measurement of DNA copy number. Nat Genet 2001;29:263-4.
22. Hackett CS, Hodgson JG, Law ME, et al. Genome-wide array CGH analysis of murine neuroblastoma reveals distinct genomic aberrations which parallel those in human tumors. Cancer Res 2003;63:5266-73.
23. Jain AN, Tokuyasu TA, Snijders AM, Segraves R, Albertson DG, Pinkel D. Fully automatic quantification of microarray image data. Genome Res 2002;12:325-32.
24. Weinstein JN, Kohn KW, Grever MR, et al. Neural computing in cancer drug development: predicting mechanism of action. Science 1992;258:447-51.
25. Bussey KJ, Kane D, Sunshine M, et al. MatchMiner: A tool for batch navigation among gene and gene product identifiers. Genome Biol 2003;4:R27.
26. Efron B, Gong G. A leisurely look at the bootstrap, the jackknife, and cross-validation. Am Stat 1983;37:36-48.
27. Westfall P, Young S. P-values adjustment for multiple tests in multivariate binomial models. J Am Stat Assoc 1989;84:780-6.
28. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B 1995;57:289-300.
29. Storey J, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5.
30. Mitelman Database of Chromosome Aberrations in Cancer. Mitelman F, Johansson B, Mertens F, editors; 2005. http://cgap.nci.nih.gov/Chromosomes/ Mitelman.
31. Zwicker J, Lucibello FC, Wolfraim LA, et al. Cell cycle regulation of the cyclin A, cdc25C and cdc2 genes is based on a common mechanism of transcriptional repression. EMBO J 1995;14:4514-22.
32. Hardeland U, Steinacher R, Jiricny J, Schar P. Modification of the human thymine-DNA glycosylase by ubiquitin-like proteins facilitates enzymatic turnover. EMBO J 2002;21:1456-64.
33. Isola J, Chu L, DeVries S, et al. Genetic alterations in ERBB2-amplified breast carcinomas. Clin Cancer Res 1999;5:4140-5.
34. Zheng JP, Robinson WR, Ehlen T, Yu MC, Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res 1991;51:4045-51.
35. Zeeberg BR, Feng W, Wang G, et al. GoMiner: a resource for biological interpretation of genomic and proteomic data. Genome Biol 2003;4:R28.
36. Wilson L, Panda D, Jordan MA. Modulation of microtubule dynamics by drugs: a paradigm for the actions of cellular regulators. Cell Struct Funct 1999;24:329-35.
37. Gupta S, Bhattacharyya B. Antimicrotubular drugs binding to Vinca domain of tubulin. Mol Cell Biochem 2003;253:41-7.
38. Cassady JM, Chan KK, Floss HG, Leistner E. Recent developments in the maytansinoid antitumor agents. Chem Pharm Bull (Tokyo) 2004;52:1-26.
39. Blower PE, Yang C, Fligner MA, et al. Pharmacogenomic analysis: correlating molecular substructure classes with microarray gene expression data. Pharmacogenomics J 2002;2:259-71.
40. Hyman E, Kauraniemi P, Hautaniemi S, et al. Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Res 2002;62:6240-5.
41. Pollack JR, Sorlie T, Perou CM, et al. Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors. Proc Natl Acad Sci U S A 2002;99:12963-8.
42. Phillips JL, Hayward SW, Wang Y, et al. The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res 2001;61:8143-9.
43. Ulger C, Toruner GA, Alkan M, et al. Comprehensive genome-wide comparison of DNA and RNA level scan using microarray technology for identification of candidate cancer-related genes in the HL-60 cell line. Cancer Genet Cytogenet 2003;147:28-35.
44. Waters TR, Gallinari P, Jiricny J, Swann PF. Human thymine DNA glycosylase binds to apurinic sites in DNA but is displaced by human apurinic endonuclease 1. J Biol Chem 1999;274:67-74.
45. Hardeland U, Bentele M, Jiricny J, Schar P. Separating substrate recognition from base hydrolysis in human thymine DNA glycosylase by mutational analysis. J Biol Chem 2000;275:33449-56.
46. Gazdar AF. The molecular and cellular basis of human lung cancer. Anticancer Res 1994;14:261-7.
47. Ritland SR, Rowse GJ, Chang Y, Gendler SJ. Loss of heterozygosity analysis in primary mammary tumors and lung metastases of MMTV-MTAg and MMTV-neu transgenic mice. Cancer Res 1997;57:3520-5.
48. Capizzi RL, Bertino JR, Handschumacher RE. L-asparaginase. Annu Rev Med 1970;21:433-44.
49. Cooney DA, Handschumacher RE. L-asparaginase and L-asparagine metabolism. Annu Rev Pharmacol 1970;10:421-40.
50. Atkin NB, Baker MC. Chromosome 7q deletions: observations on 13 malignant tumors. Cancer Genet Cytogenet 1993;67:123-5.
51. Kerr J, Leary JA, Hurst T, et al. Allelic loss on chromosome 7q in ovarian adenocarcinomas: two critical regions and a rearrangement of the PLANH1 locus. Oncogene 1996;13:1815-8.
52. Edelson MI, Scherer SW, Tsui LC, et al. Identification of a 1300 kilobase deletion unit on chromosome 7q31.3 in invasive epithelial ovarian carcinomas. Oncogene 1997;14:2979-84.
53. Watson RH, Neville PJ, Roy WJ, Jr., Hitchcock A, Campbell IG. Loss of heterozygosity on chromosomes 7p, 7q, 9p and 11q is an early event in ovarian tumorigenesis. Oncogene 1998;17:207-12.
54. Hauptmann S, Denkert C, Koch I, et al. Genetic alterations in epithelial ovarian tumors analyzed by comparative genomic hybridization. Hum Pathol 2002;33:632-41.